
zzso is a zzso of zzso and the fatty acid, zzso zzso zzso studies have demonstrated increased activity, relative to zzso with the potential for an improved therapeutic zzso We conducted a phase I study to determine the maximum tolerated doses of zzso and zzso when administered in zzso Two zzso of patients were zzso zzso zzso 5 with zzso zzso zzso zzso and zzso zzso 5 with zzso 880 zzso zzso Both drugs were given on day 1 every 21 zzso A total of 15 patients were enrolled with a median age of 59 years zzso zzso All patients had advanced cancer zzso to standard treatment, performance status 0-2 and were without major organ zzso A total of 54 cycles of treatment were zzso No zzso toxicity zzso was seen in the first cohort of three zzso In an expanded second zzso zzso was the main zzso occurring in the first cycle of treatment in five of 12 zzso three of these patients and one additional patient also experienced zzso grade 3 transient rises in liver zzso No zzso was seen and one patient developed clinically significant zzso One partial response was seen in a patient with advanced zzso of the zzso junction and 12 patients had stable disease with a median time to progression of 184 days zzso zzso zzso The recommended phase II dose in zzso patients is zzso zzso 5 and zzso zzso zzso zzso given every 21 zzso Further studies with zzso zzso 5 and zzso 880 zzso zzso given every 28 days, are warranted in zzso zzso 

